A5056936160- PARP inhibition in cancer therapy
- Cancer Research and Treatments
- Ferroptosis and cancer prognosis
- Computational Drug Discovery Methods
- Epigenetics and DNA Methylation
- Cancer, Hypoxia, and Metabolism
- Cancer-related Molecular Pathways
- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
- CAR-T cell therapy research
- Angiogenesis and VEGF in Cancer
- Immune Cell Function and Interaction
- Nanoparticle-Based Drug Delivery
- T-cell and Retrovirus Studies
- Vector-Borne Animal Diseases
- Animal Disease Management and Epidemiology
- Cancer-related gene regulation
- Genomics and Chromatin Dynamics
- Ubiquitin and proteasome pathways
- Cancer therapeutics and mechanisms
- Cancer, Lipids, and Metabolism
- RNA modifications and cancer
- TGF-β signaling in diseases
- Cancer Cells and Metastasis
University of Colorado Anschutz Medical Campus
2008-2024
University of Colorado Denver
2009-2024
Tokyo Medical and Dental University
1996-2008
University of Colorado Health
2008
Six1 is a developmentally regulated homeoprotein with limited expression in most normal adult tissues and frequent misexpression variety of malignancies. Here we demonstrate, using bitransgenic mouse model, that human mammary gland epithelium induces tumors multiple histological subtypes dose-dependent manner. The neoplastic lesions induced by had an situ origin, showed diverse differentiation, exhibited progression to aggressive malignant neoplasms, as often observed carcinoma the breast....
Mammary-specific overexpression of Six1 in mice induces tumors that resemble human breast cancer, some having undergone epithelial to mesenchymal transition (EMT) and exhibiting stem/progenitor cell features. cancer cells promotes EMT metastatic dissemination. We hypothesized plays a role the tumor initiating (TIC) population specifically certain subtypes by understanding its mechanism action, we could potentially develop new means target TICs.We examined gene expression datasets determine...
Triple-negative breast cancers, particularly the claudin-low subtype, are highly aggressive and exhibit increased tumor-initiating cell (TIC) characteristics. In this study, we demonstrate that vascular endothelial growth factor C (VEGF-C) is expressed in cancer subtype also it mediates tumor progression, not only through its role lymphangiogenesis but regulating TIC characteristics response to reactive oxygen species (ROS). VEGF expression was examined subtypes, a signature derived. and/or...
The transcription factor E2F links the RB pathway to p53 upon loss of function pRB, thereby playing a pivotal role in suppression tumorigenesis. fulfills major cell proliferation by controlling variety growth-associated genes. activity is controlled tumor suppressor which binds and actively suppresses target gene expression, restraining proliferation. Signaling pathways originating from growth stimulative suppressive signals converge on pRB (the pathway) regulate activity. In most cancers,...
<p>M1/M2 macrophages convey differential survival outcomes. M1/M2 gating strategy. CD68 of monocytes in culture system.</p>
<p>Nanostring</p>
<p>Antibodies</p>
<p>Modulation of CBX2 enhances monocyte infiltration</p>
<p>CBX2 binds to promoter regions of cytokine genes and CBX2 is significantly associated with immune signatures.</p>
<p>Primers</p>
<p>In vivo modeling with loss of CBX2 expression and Nanostring pathway analysis</p>
<p>CBX2 expression associates with epithelial state 6. CBX2 protein does not correlate T cell infiltration. CXCL1, 5, and CXCL8 correlation Macrophage M0_CIBERSORT infiltration.</p>
<p>TIMERv2</p>
<p>Overview of supplementary data</p>
The transactivator protein Tax of human T-cell leukemia virus type I plays an important role in the development adult probably through modulation growth regulatory molecules including p16<sup>INK4a</sup>. molecular mechanism leukemogenesis induced by has yet to be elucidated. We analyzed function cell cycle using interleukin-2 (IL-2)-dependent line (Kit 225) that can undergo arrest at G<sub>0</sub>/G<sub>1</sub> phase deprivation IL-2. activated endogenous E2F activity IL-2-starved Kit 225...